Ömer Kasalak1, Amelie Dammann1, Hugo J A Adams2, Jelle Overbosch1, Rudi A J O Dierckx1, Paul C Jutte3, Thomas C Kwee4. 1. Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. 2. Department of Radiology and Nuclear Imaging, Deventer Hospital, Deventer, The Netherlands. 3. Department of Orthopedics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. thomaskwee@gmail.com.
Abstract
PURPOSE: To determine the frequency of locally recurrent Ewing sarcoma on surveillance MRI and the outcome of these patients. MATERIALS AND METHODS: This retrospective single-center study included all patients with newly diagnosed Ewing sarcoma who underwent surveillance MRI of the primary tumor location after primary treatment between 1997 and 2016. RESULTS: Thirty-two patients underwent a total of 176 local surveillance MRI scans, yielding an average of 5.5 ± 4.4 MRI scans per patient. Follow-up time of surveillance MRI after completion of primary treatment ranged between 1 and 111 months. Surveillance MRI detected five (15.6%) locally recurrent Ewing sarcomas, at 2, 4, 6, 6, and 7 months after completion of primary treatment, of whom three also had simultaneous recurrent (metastatic) disease elsewhere. Two patients had recurrent metastatic disease without any signs of locally recurrent disease on surveillance MRI. All five patients with locally recurrent disease on surveillance MRI died, at 2, 4, 5, 8, and 9 months after local recurrence detection. Patients with locally recurrent disease had a significantly worse overall survival than patients without locally recurrent disease (log-rank test, P < 0.0001). CONCLUSIONS: A limited number of patients have locally recurrent Ewing sarcoma on surveillance MRI. These patients often have simultaneous recurrent (metastatic) disease elsewhere, and their outcome is poor. Moreover, some patients present without locally recurrent disease on MRI but disease recurrence elsewhere. Therefore, surveillance MRI currently seems to have little value and should be reconsidered, also given the costs and the repeated exposure of surviving patients to gadolinium-based contrast agents.
PURPOSE: To determine the frequency of locally recurrent Ewing sarcoma on surveillance MRI and the outcome of these patients. MATERIALS AND METHODS: This retrospective single-center study included all patients with newly diagnosed Ewing sarcoma who underwent surveillance MRI of the primary tumor location after primary treatment between 1997 and 2016. RESULTS: Thirty-two patients underwent a total of 176 local surveillance MRI scans, yielding an average of 5.5 ± 4.4 MRI scans per patient. Follow-up time of surveillance MRI after completion of primary treatment ranged between 1 and 111 months. Surveillance MRI detected five (15.6%) locally recurrent Ewing sarcomas, at 2, 4, 6, 6, and 7 months after completion of primary treatment, of whom three also had simultaneous recurrent (metastatic) disease elsewhere. Two patients had recurrent metastatic disease without any signs of locally recurrent disease on surveillance MRI. All five patients with locally recurrent disease on surveillance MRI died, at 2, 4, 5, 8, and 9 months after local recurrence detection. Patients with locally recurrent disease had a significantly worse overall survival than patients without locally recurrent disease (log-rank test, P < 0.0001). CONCLUSIONS: A limited number of patients have locally recurrent Ewing sarcoma on surveillance MRI. These patients often have simultaneous recurrent (metastatic) disease elsewhere, and their outcome is poor. Moreover, some patients present without locally recurrent disease on MRI but disease recurrence elsewhere. Therefore, surveillance MRI currently seems to have little value and should be reconsidered, also given the costs and the repeated exposure of surviving patients to gadolinium-based contrast agents.
Authors: G Bacci; A Longhi; S Ferrari; M Mercuri; E Barbieri; F Bertoni; P Bacchini; P Picci Journal: Eur J Surg Oncol Date: 2006-04-18 Impact factor: 4.424
Authors: Maria Camilla Rossi Espagnet; Bruno Bernardi; Luca Pasquini; Lorenzo Figà-Talamanca; Paolo Tomà; Antonio Napolitano Journal: Pediatr Radiol Date: 2017-05-19
Authors: Vikas Gulani; Fernando Calamante; Frank G Shellock; Emanuel Kanal; Scott B Reeder Journal: Lancet Neurol Date: 2017-06-13 Impact factor: 44.182
Authors: Nathalie Gaspar; Douglas S Hawkins; Uta Dirksen; Ian J Lewis; Stefano Ferrari; Marie-Cecile Le Deley; Heinrich Kovar; Robert Grimer; Jeremy Whelan; Line Claude; Olivier Delattre; Michael Paulussen; Piero Picci; Kirsten Sundby Hall; Hendrik van den Berg; Ruth Ladenstein; Jean Michon; Lars Hjorth; Ian Judson; Roberto Luksch; Mark L Bernstein; Perrine Marec-Bérard; Bernadette Brennan; Alan W Craft; Richard B Womer; Heribert Juergens; Odile Oberlin Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544